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A B S T R A C T
Recent reports indicate that 7% of pregnant mothers in North America use cannabis. This is concerning given that
in utero exposure to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive component in cannabis, causes
fetal growth restriction and may alter replication and survival of pancreatic β-cells in the offspring. Accordingly,
we hypothesized that maternal exposure to Δ9-THC during pregnancy would impair postnatal glucometabolic
health of offspring. To test this hypothesis, pregnant Wistar rats were treated with daily intraperitoneal injec-
tions of either 3 mg/kg Δ9-THC or vehicle from gestational day 6 to birth. Offspring were subsequently chal-
lenged with glucose and insulin at 5 months of age to assess glucose tolerance and peripheral muscle insulin
sensitivity. Female offspring exposed to Δ9-THC in utero were glucose intolerant, associated with blunted insulin
response in muscle and increased serum insulin concentration 15 min after glucose challenge. Additionally,
pancreata from male and female offspring were harvested at postnatal day 21 and 5 months of age for assessment
of endocrine pancreas morphometry by immunostaining. This analysis revealed that gestational exposure to Δ9-
THC reduced the density of islets in female, but not male, offspring at postnatal day 21 and 5 months, culmi-
nating in reduced β-cell mass at 5 months. These results demonstrate that fetal exposure to Δ9-THC causes
female-specific impairments in glucose homeostasis, raising concern regarding the metabolic health of offspring,
particularly females, exposed to cannabis in utero.
1. Introduction
Recent reports indicate that 7% of pregnant mothers in North
America, and 19 % of those aged 18–24, use cannabis [1]. Much of this
use may be motivated by the belief that cannabis eases nausea, vo-
miting, and lost appetite during pregnancy [2], in conjunction with
media portrayals of cannabis as a natural alternative to pharmaceuticals
[3,4]. A recent integrative review also concluded that women who used
cannabis during pregnancy did so given the perception that there were
no significant risks to the mother or fetus [5]. However, little is known
regarding the effects of cannabis and its constituent compounds on
postnatal outcomes.
We and others have recently demonstrated in rodents that Δ9-tet-
rahydrocannabinol (Δ9-THC), the main psychoactive component of
cannabis, leads to fetal growth restriction, in part, due to placental in-
sufficiency [6,7]. This is pertinent because since 1995, selective
breeding has increased Δ9-THC content in cannabis from 4% to 12 %
[8]. Given the strong association between impaired fetal growth and
the development of type 2 diabetes [9], this raises concern regarding
the metabolic health of offspring exposed to Δ9-THC in utero. In addi-
tion, Δ9-THC may directly influence development of the fetal pancreas,
through its interaction with the cannabinoid 1 receptor (CB1R)
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[10–12].
CB1R is expressed by both insulin-producing β-cells and glucagon-
producing α-cells [13], and contributes to islet formation and organi-
zation during fetal development [10]. Moreover, CB1R activation sup-
presses mitogenic signaling in β-cells, while also promoting apoptosis
[11,12]. In a healthy fetus, these effects of CB1R are modulated by
temporally-controlled endogenous endocannabinoid levels in fetal
tissue and circulation [10,14,15]. However, studies indicate that Δ9-
THC readily traverses the placental barrier and 10–28 % of maternal
concentrations are detected in the fetal plasma, with 2−5X higher
concentrations in fetal tissues [16–18]. This would allow maternal Δ9-
THC to potentially dysregulate physiologic control of CB1R and its
downstream processes within the developing fetal pancreas. Given that
the long-term effects of Δ9-THC on metabolic organs outside of the
brain remain elusive, we investigated the impact of in utero exposure to
Δ9-THC on the development of the endocrine pancreas, including its
impact on whole-body glucose metabolism in the offspring.
2. Research design and methods
2.1. Animals
All procedures were performed in accordance with the guidelines of
the Canadian Council of Animal Care. Female Wistar rats were pur-
chased from Charles River (La Salle) and throughout the experimental
procedure were maintained at 22 °C on a 12:12-h light-dark cycle with
access to food and water ad libitum. Dams were randomly assigned to
receive daily intraperitoneal (i.p.) injections of either 3 mg/kg Δ9-THC
(Sigma-Aldrich, Saint Louis) or vehicle (18:1 saline:cremophor) from
gestational day (GD) 6 to GD22. This dosage of Δ9-THC i.p. yields
maternal blood concentrations of Δ9-THC (8.6–12.4 ng/mL) compar-
able to those seen after moderate recreational cannabis smoking in
human adults (13−63 ng/mL), as well as in aborted fetal tissue
(4−287 ng/mL) after maternal cannabis use [19–21]. Administration of
Δ9-THC was delayed until GD6 since administration of the drug earlier
in pregnancy can induce spontaneous abortions [22]. We previously
demonstrated that 3 mg/kg Δ9-THC given from GD6 to GD22 does not
cause fetal demise, alterations in litter size, gestational length, or ma-
ternal weight gain [7]. Dams were allowed to deliver normally, and at
birth (postnatal day 1; PND1), pups were weighed, and litters randomly
culled to 8 offspring. Measurements at PND1 represent mixed males and
females. Offspring were killed at either PND21 or 5 months of age (5 m)
by i.p. pentobarbital overdose (100 mg/kg). 5 m was chosen as the age
for sacrifice, as this is beyond the point (130 days-of-age) when rats
have been demonstrated to exhibit sexual dimorphism in glucose in-
tolerance and β-cell mass [23]. All offspring were fasted for ∼14 h
prior to sacrifice, then weighed, the pancreas dissected, fixed in 10 %
formalin, and embedded in paraffin. Prior to sacrifice at 5 m, glycaemia
was measured with a OneTouch Ultra2 hand-held glucometer (LifeScan,
Zug, Switzerland) from blood obtained by tail vein snip. Blood was also
drawn by cardiac puncture for quantification of serum insulin by ELISA
(ALPCO, Salem, NH, USA), as well as serum estrogen (Biovision Mil-
pitas, CA, USA), and free testosterone (R&D Systems, Minneapolis, MN,
USA). Fasting glucose (FG) and insulin (FI) levels were used to calculate
HOMA1-IR by the formula HOMA1-IR = FG x FI/22.5 as a measure of
peripheral insulin resistance [24].
2.2. Intraperitoneal glucose tolerance test (IP-GTT)
Glucose homeostasis was investigated at 5 m using an in-
traperitoneal glucose tolerance test (IP-GTT). 5–6 offspring per sex per
treatment were fasted overnight (∼14 h) then allowed to acclimate in a
dark, quiet room for 2 h. Baseline blood glucose levels were obtained as
above, and 2 g/kg glucose administered by i.p. injection. Glucose levels
were taken 5, 15, 30, 60, 90, and 120 min post injection. Total glucose
response to the challenge was calculated using the trapezoidal area
under the curve (AUC) for each animal. Blood was collected from the
tail vein at 15 and 30 min after glucose bolus for quantification of
serum insulin by ELISA (Crystal Chem, Elk Grove Village, IL, USA).
2.3. Intraportal insulin challenge
To evaluate insulin sensitivity in muscle, phosphorylation of Akt
was assessed in 11 female animals (6 vehicle and 5 Δ9-THC), each from
a distinct dam, aged 5 m [25]. Rats were anaesthetized with isoflurane,
the abdominal wall dissected, and the portal vein exposed and ligated
distally. Saline was infused over 10 s and a portion of soleus muscle
harvested. Insulin, 2 U/kg Humulin (Lilly, Indianapolis, IN, USA), was
then infused over 10 s and a portion of soleus muscle was further
harvested after 1 min. Tissue samples were snap frozen in liquid ni-
trogen and kept at -80 °C.
2.4. Protein extraction and western blot
Proteins were extracted from the muscle of rats subjected to in-
traportal insulin challenge as described previously [23]. Proteins (50
μg) were separated on an 8% SDS-PAGE, transferred to nitro-cellulose
membranes, blocked for 60 min at room temperature in Tris-buffered
saline containing 0.05 % Tween 20 (TTBS) and 5% non-fat dry milk or
5% BSA, then probed overnight at 48 °C with 1:1000 anti-phospho Akt
(Ser 473) [pAkt (Ser 473)] mouse antibody or 1:1 000 anti-Akt2 rabbit
antibody (Cell Signalling Technology, New England Biolabs, Beverly,
MA, USA). Proteins were detected by enhanced chemiluminescence
(Pierce, IL, USA) with horseradish peroxidase-labelled secondary anti-
bodies (Sigma, St. Louis, MO, USA). The optical density of the bands
was quantified with a Bio Imaging Gel System (Chemi Genius II, Syn-
gene) with Gene Tools software. Each membrane was probed with an
antibody against pAkt [Ser 473], then incubated in stripping buffer
(Pierce, IL, USA) and re-probed with an antibody against Akt2 to nor-
malize the results. Results are expressed as a ratio of these optical
density values.
2.5. Immunohistochemistry and endocrine pancreas morphometry
Sections of 5 μm were cut from paraffin-embedded pancreata of
offspring harvested at PND21 and 5 m and mounted on SuperFrost Plus
glass slides (Fischer Scientific, Toronto). Two or three sections per an-
imal, separated by at least 50 μm, were deparaffinized in xylene, re-
hydrated in descending ethanol series (100 %, 90 %, 70 %), then wa-
shed in tap water prior to application of rabbit anti-glucagon IgG
(Novus Biologicals, Centennial, CO, USA) and mouse anti-insulin IgG
(Sigma-Aldrich, Saint Louis, MO, USA) primary antibodies. ImmPRESS
Duet Double Staining Kit (Vector Laboratories, Burlingame) was used to
detect insulin- and glucagon-positive cells.
Analysis of pancreatic sections was performed as described pre-
viously [23]. Briefly, a composite image of the whole section was ob-
tained using Microsoft Image Composite Editor and microphotographs
taken with a 2.5x objective lens. Under 200x magnification, all in-
dividual islets were microphotographed and FIJI (http://fiji.sc) used to
quantify the area occupied by β- and α-cells. β- and α-cell fractional
area were calculated as the total insulin- and glucagon-positive area,
respectively, divided by total pancreatic tissue area. The density of is-
lets was calculated by counting the total number of islets present on
each slide and dividing by total pancreatic tissue area. Mean islet size
and mean β-cell area per islet were calculated by dividing total islet
area (insulin- and glucagon-positive) or total β-cell area, respectively,
by the total number of islets present on each slide. β- and α-cell mass
were calculated as the product of pancreas weight and β- and α-cell
fractional area, respectively. The density of extra-islet clusters (less
than 500 μm2 or ∼5 endocrine cells) was also assessed as a marker of
endocrine cell neogenesis [26,27]. All calculations were averaged
across 2–3 slides per animal.
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To assess replication in β- and α-cells, 2–3 slides per animal, sepa-
rated by at least 50 μm, were incubated with mouse anti-Ki67 (Sigma-
Aldrich, Saint Louis, MO, USA), guinea pig anti-insulin (Abcam,
Toronto, ON, Canada), and rabbit anti-glucagon (Novus Biologicals,
Centennial, CO, USA) primary antibodies. Donkey anti-mouse 488, anti-
guinea pig 555, and anti-rabbit 647 fluorescent secondary antibodies
(Thermofisher, Toronto, ON, Canada) were then applied, and DAPI
(Thermofisher, Toronto, ON, Canada) used to counterstain nuclei.
Apoptosis in β- and α-cells was examined similarly using ApopTag
Fluorescein In Situ Apoptosis Detection Kit (Sigma-Aldrich, Saint
Louis). At least 20 randomly-selected islets per section were micro-
photographed using a Nikon Eclipse Ts2R Epifluorescence Microscope.
Manual tracing was used to outline insulin- and glucagon-positive
areas, and particle analysis and water shedding filters applied to find
and count DAPI+ nuclei within these regions [28]. Ki67+ or TUNEL+
nuclei were counted manually within each region and used to de-
termine the percentage of Ki67+ or TUNEL+ β- and α-cells. An average
of 1656 β-cells and 1201 α-cells were counted for every animal.
2.6. Statistical analysis
A sample size of 5–7 animals per sex per age group per treatment
was chosen based on achieving a statistically significant difference with
an expected standard deviation of 15 % or less, based on previous
studies [27]. Values depicted are mean± SEM and considered sig-
nificant if p< 0.05. Analysis of the data was performed using Excel
v16.16 (Microsoft) and GraphPad Prism v7 (GraphPad Software, Inc).
Unless indicated otherwise, statistical analysis was by two-way ANOVA
followed by Holm-Sidak-corrected multiple comparisons between Δ9-
THC-exposed offspring and their sex-matched controls [23].
3. Results
3.1. Fetal growth restriction and postnatal catch-up growth
Offspring bodyweight and pancreatic weight were measured at
birth, at weaning on PND21, and in young adulthood at 5 m.
Gestational exposure to Δ9-THC significantly reduced both birth-
weights (Fig. 1A; 6.62±0.11 g for Δ9-THC and 7.02± 0.11 g for ve-
hicle, p = 0.0135) and pancreatic weights (Fig. 1 D; 12.18±1.54 mg
for Δ9-THC vs 17.33±1.62 mg for vehicle, p = 0.029) in male and
female offspring. By PND21, Δ9-THC-exposed offspring recovered in
terms of both bodyweight and pancreatic weight (Fig. 1 B, E), and
thereafter maintained comparable weights to that of their sex-matched
controls (Fig. 1 C, F). Male did not differ from female offspring in
bodyweight or pancreatic weight at PND21, therefore results are
pooled.
3.2. Impaired glucose homeostasis
To determine the impact of in utero Δ9-THC exposure on glucose
metabolism in postnatal life, blood glucose levels were examined after
∼14 h of fasting in adulthood, and offspring underwent an IP-GTT.
Exposure to Δ9-THC was associated with a decrease in fasting blood
glucose at 5 m (p = 0.0393 for effect of Δ9-THC by two-way ANOVA),
though differences did not achieve statistical significance for either
males or females when evaluated independently (Table1). Fasting in-
sulin levels, however, were not affected by gestational exposure to Δ9-
THC (Table 1), and HOMA1-IR scores were also not different between
vehicle and Δ9-THC-exposed offspring in males or females (data not
shown). Following glucose challenge, female offspring exposed to Δ9-
THC exhibited elevated blood glucose at 5 min (18.37±1.74 mmol/L
for Δ9-THC vs 11.48±0.84 mmol/L for vehicle, adjusted p value =
0.0496), as well as an overall increased area under the curve for blood
glucose (Fig. 2A). This was associated with significantly augmented
serum insulin concentration compared to vehicle offspring 15 min after
glucose challenge (0.47±0.05 ng/mL for Δ9-THC vs 0.29± 0.07 for
vehicle, adjusted p value = 0.0264), but which subsided to normal
levels by 30 min (Fig. 2 B). No similar alterations were present in males
(Fig. 2 C, D).
Given the alterations in glucose tolerance and serum insulin con-
centration in Δ9-THC-exposed female offspring, peripheral insulin
sensitivity in the soleus muscle was examined after insulin challenge in
Fig. 1. Gestational exposure to Δ9-THC re-
duces birthweight and pancreatic weight
which is followed by catch-up growth.
Bodyweight (A, B, C) and pancreatic weight (D,
E, F) at PND1, PND21, and 5 m. *, p<0.05 for
vehicle vs Δ9-THC assessed by Student’s t test.
Values are mean±SEM. n = mean of 4-5 lit-
ters per treatment (PND1), 16-23 individuals
per treatment (PND21), 7-8 individuals per
treatment per sex (5 m).
Table 1
Fasting blood glucose, insulin, and sex steroid levels at 5 m in male and female
offspring. T, p< 0.05 for effect of gestational Δ9-THC exposure; S, p< 0.05 for
effect of sex by two-way ANOVA. Values are mean± SEM.
Female Male Two-way
ANOVA
Vehicle Δ9-THC Vehicle Δ9-THC
Fasting Glucose
(mmol/L)
6.038±
0.2419
5.49±
0.2157
6.064±
0.155
5.714±
0.1079
T
n = 13 10 14 7
Fasting Insulin (ng/
mL)
1.335±
0.2164
1.473±
0.2115
2.208±
0.4498
2.253±
0.5146
S
n = 8 10 12 6
Fasting Estrogen (pg/
mL)
57.34±
5
57.75±
4
N/A N/A N/A
n = 11 10
Fasting Testosterone
(ng/mL)
3.4± 5 3.1±
0.7
N/A N/A N/A
n = 9 7
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these animals via phosphorylated Akt [Ser 473], a hallmark of insulin
receptor activation and sensitivity [25]. Female Δ9-THC-exposed off-
spring exhibited a significantly reduced ratio of pAkt [Ser 473] relative
to total Akt2 protein expression after insulin challenge (Fig. 3;
0.58±0.22 for Δ9-THC vs 2.56±0.64 for vehicle, adjusted p value =
0.0031).
Given the importance of estrogen and testosterone for glucose tol-
erance and preservation of β-cells [29–31], we also quantified fasting
estrogen and testosterone levels at 5 m. However, analysis revealed that
estrogen and testosterone were unaltered in female offspring (Table 1),
and both levels obtained were similar to those previously reported in
young adult Wistar rats [23].
3.3. Altered endocrine pancreatic development
In female offspring, gestational Δ9-THC exposure reduced the total
density of islets at both PND21 (2.23±0.17 islets/mm2 for Δ9-THC vs
2.78±0.19 islets/mm2 for vehicle, adjusted p value = 0.0247) and 5
m (1.32±0.10 islets/mm2 for Δ9-THC vs 1.94±0.22 islets/mm2 for
vehicle, adjusted p value = 0.0002), attributable to a specific decrease
in the density of small islets (Fig. 4A, G). By 5 m, this decrease in total
islet density culminated in a reduction in β-cell mass in female Δ9-THC-
exposed offspring (Fig. 4 H; 6.68± 0.71 mg for Δ9-THC vs
11.32±1.76 mg for vehicle, adjusted p value = 0.0332). No equiva-
lent alterations were apparent in male offspring (Fig. 4). This reduction
in β-cell mass in female Δ9-THC-exposed offspring was attributable
Fig. 2. Gestational exposure to Δ9-THC causes
glucose intolerance exclusively in female off-
spring at 5 months of age associated with in-
creased serum insulin 15 min after glucose
challenge. Blood glucose levels and integrated
area under the curve for blood glucose tracked
for 120 min following 2 g/kg glucose challenge
in female and male offspring aged 5 months (A,
C). Serum insulin concentrations 15 and 30
min after glucose challenge (B, D). *, p<0.05
for vehicle vs Δ9-THC assessed by repeated
measures two-way ANOVA and Holm-Sidak-
corrected post-hoc tests, or Student’s t test
(AUC). Values are mean± SEM. n = 4-6 per
treatment per sex.
Fig. 3. Gestational exposure to Δ9-THC im-
pairs insulin response in muscle in female off-
spring aged 5 months. Ratio of phosphorylated
Akt [Ser 473] relative to total Akt2 protein
levels. **, p<0.01; ns, not significant for ve-
hicle vs Δ9-THC assessed by two-way ANOVA
and Holm-Sidak-corrected post-hoc tests.
Values are mean± SEM. n = 5-6 per treat-
ment, where each n value represents one off-
spring per dam.
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exclusively to a reduction in the total number of islets, as mean islet size
and mean β-cell area per islet were found to be unchanged at both
weaning and in adulthood (Table 2).
To gain insight into possible mechanisms involved in the observed
reductions in islet density and β-cell mass in Δ9-THC-exposed females,
endocrine cell neogenesis, as well as β- and α-cell replication and
apoptosis were examined. Neogenesis was assessed via the density of
extra-islet clusters (< 500 μm2) [26,27], and was found to be unaltered
at either PND21 or 5 m (Table 2). Pancreatic islet replication and
apoptosis were examined in PND21 female offspring by im-
munohistochemistry with Ki67 antibody and TUNEL assay, respectively
(Fig. 5A (Ki67) and B (TUNEL)). PND21 was chosen given the reduction
in islet density at this age and that replication and apoptosis in α- and β-
cells declines markedly after this age [32,33]. Neither the percentage of
β-cells (Ins+) or α-cells (Glucagon+) positive for Ki67 (Fig. 5 C, D), nor
the percentage of β-cells (Ins+) positive for TUNEL (Fig. 5 E) were
Fig. 4. Gestational exposure to Δ9-THC reduces small islet and total islet density at PND21 and 5 m, and reduces β-cell mass at 5 m exclusively in female offspring.
Density of small (500-5 000 μm2), medium (5 000 - 10 000 μm2), large (> 10 000 μm2), and total islets for female (A, G) and male (D, J) offspring at PND21 and 5 m.
β-cell mass (B, E, H, K) and α-cell mass (C, F, I, L) in female and male offspring at PND21 and 5 m. *, p<0.05; ***, p<0.001 for vehicle vs Δ9-THC assessed by
repeated measures two-way ANOVA and Holm-Sidak-corrected post-hoc tests. Values are mean± SEM. n = 4-7 per treatment per sex per age (2-3 technical
replicates per animal), where each n value represents one offspring per dam.
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altered following Δ9-THC exposure. No TUNEL-positive α-cells were
observed in either group.
4. Discussion
Considering the increased popularity of cannabis in pregnancy [1],
and the rising concentration of Δ9-THC in cannabis over the last two
decades [8], it is essential to understand the long-term metabolic effects
of gestational exposure to this specific cannabinoid. In the current
study, we and others utilized a physiologically-relevant dosage of Δ9-
THC (3 mg/kg) which yields maternal blood concentrations of Δ9-THC
(8.6–12.4 ng/mL), which are comparable to those seen after moderate
recreational cannabis smoking in human adults (13−63 ng/mL), as well
as in the tissue of aborted fetuses after maternal cannabis use (4−287
ng/mL) [19–21,34–36]. Previous studies in humans as well as animals
have demonstrated that Δ9-THC readily crosses the placenta, and that
10–28 % of maternal concentrations are detected in the fetal plasma,
with 2−5X higher concentrations in fetal tissues [16–18]. However,
given evidence that fetal plasma concentrations of Δ9-THC may depend
on the route of maternal exposure [16,37–39], quantification of Δ9-
THC in fetal circulation after maternal i.p. Δ9-THC exposure would add
insight to the results obtained in the present study. Nevertheless, this
lower dosage of Δ9-THC (3 mg/kg) led to fetal growth restriction, and
unlike other studies employing 5 mg/kg [6], it did so without fetal de-
mise [7]. Additionally, it should be noted that in same cohort of vehicle
and Δ9-THC offspring, we have published that Δ9-THC exposure in
pregnancy did not lead to changes in maternal food intake, maternal
weight gain, or gestational length [7]. In this cohort, we now demon-
strate alterations in endocrine pancreatic development culminating in
decreased β-cell mass, impaired glucose tolerance, and aberrant insulin
response in adult female Δ9-THC-exposed offspring.
At birth, both male and female offspring exposed to Δ9-THC had
reduced bodyweight and pancreatic weight. We have previously de-
monstrated that Δ9-THC-exposed offspring also exhibit significant de-
creases in brain to bodyweight ratio, and liver to bodyweight ratio,
indicative of symmetrical intrauterine growth restriction [7]. Both male
and female Δ9-THC-exposed offspring underwent catch-up growth by
PND21, but only females were glucose intolerant at 5 m. Specifically, 5-
month-old females exposed to Δ9-THC exhibited elevated blood glucose
5 min after glucose challenge and overall elevated area under the curve
Table 2
Endocrine pancreas morphometry in female and male offspring at PND21 and 5 m. S, p< 0.05 for effect of sex by two-way ANOVA; ns, not significant. Values are
mean± SEM. n = 4-7 per treatment per sex (2-3 slides per animal).
Female Male Two-way ANOVA
Δ9-THC Vehicle Δ9-THC Vehicle
Mean Islet Size (μm2) PND21 3627±272.5 3592±349.5 4537±471.3 3995±147.4 ns
5 m 6322±533.2 7341±514.2 8394±861 7228±236.4 ns
Mean β-cell Area per Islet (μm2) PND21 2226±117.8 2750±381.6 3326±243.9 2812±163.5 S
5 m 4999±488.1 5781±453.1 6691±538.8 6000±34.89 ns
Clusters per mm2 Pancreas PND21 4.092± 0.5584 3.256±0.6557 2.603± 0.1859 2.852±0.1772 S
5 m 0.795±0.1543 0.802±0.0814 0.644± 0.1359 0.689±0.134 ns
Fig. 5. Gestational exposure to Δ9-THC does not alter replication or apoptosis in β- or α-cells in females at PND21. Representative immunohistochemistry of an islet
immunostained for Ki67 (A) and TUNEL (B). Percentage of β-cells positive for Ki67 (C); percentage of α-cells positive for Ki67 (D); percentage of β-cells positive for
TUNEL (E). Values are mean±SEM. n = 4-5 per treatment (2-3 technical replicates per animal), where each n value represents one offspring per dam.
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for blood glucose. Interestingly, this occurred in association with in-
creased serum insulin 15 min after glucose challenge, suggesting that
peripheral insulin resistance, leading to impaired glucose disposal,
contributes to the observed glucose intolerance. To explore this further,
we challenged vehicle and Δ9-THC-exposed female offspring with in-
sulin and found that Δ9-THC-exposed offspring demonstrated blunted
pAkt [Ser473] activation, a hallmark of insulin receptor activation and
sensitivity [25], in the soleus muscle.
In addition to the observed impairments in downstream insulin
signaling, Δ9-THC-exposed females also exhibited altered development
of the endocrine pancreas. Specifically, these Δ9-THC female offspring
had decreased total and small islet density at both PND21 and 5 m,
along with a significant reduction (41 %) in β-cell mass at 5 m. Despite
this decrease in β-cell mass, fasting serum insulin levels were main-
tained, suggesting some degree of β-cell compensation [40]. Other
studies have shown that this type of β-cell compensation is implicated
in eventual β-cell exhaustion [41], which along with chronic glucose
intolerance, culminates in β-cell death [42], or dedifferentiation [43]
seen in the progression from prediabetes to overt type 2 diabetes. It will
therefore be interesting to explore the future metabolic health of these
offspring in later life (i.e.>6 months of age).
The sexual dimorphism observed in this study is noteworthy as it
has previously been demonstrated that female offspring exposed to Δ9-
THC in utero exhibit neurodevelopmental abnormalities pertaining to
addiction, while their male counterparts do not, suggesting that female
offspring may be more sensitive to the effects of Δ9-THC in utero [44].
Based on the collective results of this current study, the mechanisms
responsible for the reductions in islet density and β-cell mass in female
Δ9-THC-exposed offspring remain elusive. While decreases in estrogen
are associated with β-cell apoptosis [30], no changes were apparent in
either estrogen or testosterone levels, and no alterations were apparent
in postnatal (PND21) β- or α-cell replication, neogenesis, or apoptosis.
This contrasts with what is observed in offspring exposed to another
psychoactive compound, nicotine. When administered during gestation,
nicotine-exposed offspring exhibit reduced β-cell mass at four weeks of
age, but not 26 weeks of age, due to compensatory increased islet cell
proliferation at four weeks [45]. However, this compensatory me-
chanism is not seen when nicotine exposure extends through lactation,
and islet cell apoptosis is now increased at 4 weeks of age, resulting in
reduced β-cell mass from 4 to 26 weeks [45]. Despite lacking any such
alterations in islet cell proliferation, apoptosis, or neogenesis, we still
observed reduced islet density in both PND21 and 5 m female Δ9-THC
exposed offspring. It is therefore likely that the glucometabolic effects
of Δ9-THC incurred earlier during prenatal development. For example
in a model of maternal malnutrition (total caloric intake reduced to 50
% of controls), fetal growth restricted offspring exhibited reduced β-cell
mass at birth (PND1) and PND21, attributable to reduced islet density
and β-cell size, with no alterations present in β-cell replication at PND1
or PND21 [46,47]. Δ9-THC may be particularly deleterious to β-cell
development during prenatal life, first due to the effects of Δ9-THC on
placental insufficiency leading to less maternal transfer of oxygen and
nutrients for fetal pancreatic development [6,7]. This is consistent with
the thrifty phenotype hypothesis, in which adaptations suited to mal-
nutrition in utero contribute to metabolic disease in later life [48].
Noteworthy for the present study are adaptations concerning the en-
docrine pancreas, namely reduced β-cell mass and reduced β-cell
number at 90 % gestation, as observed in growth-restricted fetal sheep
[49]. Similar adaptations may contribute to the altered endocrine
pancreatic development as seen in our Δ9-THC-exposed female off-
spring, warranting further investigation related to perinatal windows of
Δ9-THC exposure. Secondly, Δ9-THC in utero may have direct adverse
glucometabolic effects on the developing fetal pancreas via its inter-
action with CB1R [11,12]. In particular, in vitro studies have shown that
CB1R activation suppresses mitogenic signaling in β-cells via decreased
expression of cyclin D2 and impaired downstream insulin signaling, and
promotes apoptosis through decreased expression of Bcl-2 [11,12]. As
such, there is potential for a direct impact of Δ9-THC on development of
the fetal endocrine pancreas, but further work is needed to investigate if
such alterations are apparent in the fetal pancreas after Δ9-THC ex-
posure in vivo.
5. Conclusion
In summary, though to date no associations have yet been found
between maternal cannabis use and offspring development of type 2
diabetes in humans, future prospective clinical studies are warranted
given that the major increases in Δ9-THC content in cannabis have only
occurred over the past two decades. This is the first study to demon-
strate a link between maternal Δ9-THC exposure and predisposition to
develop glucose intolerance in female offspring. This raises concern
about the future metabolic health of offspring exposed to Δ9-THC in
utero, particularly as this study examined the effects of Δ9-THC at levels
which are conservative estimates of what is available in recreational
cannabis today.
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